+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Basal Cell Carcinoma Pipeline Analysis and Outlook, 2019

  • PDF Icon


  • 102 Pages
  • May 2019
  • Region: Global
  • VPA Research
  • ID: 4772471
Basal Cell Carcinoma pipeline

Basal Cell Carcinoma pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Basal Cell Carcinoma R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Basal Cell Carcinoma report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Basal Cell Carcinoma as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Basal Cell Carcinoma with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Basal Cell Carcinoma pipeline Profiled in detail

Key players actively participating in Basal Cell Carcinoma pipeline are profiled along with their R&D progress in Basal Cell Carcinoma treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Basal Cell Carcinoma pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Basal Cell Carcinoma treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Basal Cell Carcinoma pipeline and treatment landscape

  • Complete list of drug candidates from discovery to pre-registration phases are analyzed

  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio

  • Detailed drug profiles of Basal Cell Carcinoma pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed

  • Research and Development progress and trial details, results wherever available, are also included in the Basal Cell Carcinoma pipeline study

  • All recent news and developments related to Basal Cell Carcinoma drugs are provided

Table of Contents

1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019
2. Basal Cell Carcinoma Disease Overview
3. Basal Cell Carcinoma Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019
4. Basal Cell Carcinoma Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History
5. Basal Cell Carcinoma Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History
6. Company Profiles
6.1. Basal Cell Carcinoma companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Basal Cell Carcinoma Activities
7. Recent News Landscape
8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services

Companies Mentioned

  • 4SC AG

  • Adgero Biopharmaceuticals Holdings Inc

  • Amgen Inc

  • Biofrontera AG

  • Biosceptre International Ltd

  • Bristol-Myers Squibb Co

  • Cannabis Science Inc

  • Galderma SA

  • HedgePath Pharmaceuticals Inc

  • Leaf Vertical Inc

  • LEO Pharma A/S

  • Loxo Oncology Inc

  • Mayne Pharma Group Ltd

  • MediGene AG

  • Medivir AB

  • Merck & Co Inc

  • Ojer Pharma SL

  • Oshadi Drug Administration Ltd

  • PellePharm Inc

  • Regeneron Pharmaceuticals Inc

  • Replimune Ltd

  • Senhwa Biosciences Inc

  • Transgene SA